2007 Biosimilars Compounding 
Putting Patients First Blog
JUNE 26, 2025
At the same time, the NHC recommends that CMS avoid incorporating the MFP into ASP calculations, as doing so could depress reimbursement rates across both Medicare and commercial markets, compounding access risks and straining provider viability. 1 (July 4, 2007): 61– 69, [link] 48 U.S. Goldman, Geoffrey F.
Pharmacy Times
AUGUST 15, 2025
Image Credit: Grandbrothers | stock.adobe.com The study looked at 186 adolescents from the Teen-LABS group who had bariatric surgery between 2007 and 2012. This research shows how the environment plays a role in the results of weight surgery in young people over time.¹
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 29, 2025
According to findings of a study cited by Joober et al, the frequency of papers declaring significant statistical support for their a priori formulated hypotheses increased by 22% between 1990 and 2007 (n = 4656; P < 001). 2018;153(7):663-670. doi:10.1001/jamasurg.2018.0040
Pharmaceutical Technology
JULY 23, 2008
Demand for treatment The American Cancer Society estimates that over 12 million new cancer cases were diagnosed worldwide in 2007. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. . And are we getting any closer to beating the Big C?
pharmaphorum
DECEMBER 2, 2020
It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.
Expert insights. Personalized for you.
Let's personalize your content